Rituximab versus avatrombopag for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study compares two medicines for adults with newly diagnosed ITP (a low platelet count that can cause bleeding). One medicine is rituximab, which helps the immune system stop attacking platelets, and the other is avatrombopag, which helps the body make more platelets. You may join if your platelet count is very low and standard steroid treatment hasn't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with ITP within the last year.
- Your platelet count is below 30 (a measure of bleeding risk) and has not improved enough after trying a steroid treatment, or it dropped again.
- You have not had certain stronger treatments before (like rituximab, most immune-suppressing drugs, chemotherapy, or spleen removal). If you had a rescue treatment with a platelet-boosting drug for emergencies, that is okay as long as it was for less than two weeks.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control for at least a year after the study treatment.
- You do not have ITP caused by other conditions (like lupus, HIV, hepatitis C, or certain cancers), and you do not have active hepatitis B (hepatitis B is okay if you are willing to take preventive medication).
- You do not have other serious medical conditions that could be worsened by the study drugs, and you have no known allergies to rituximab or avatrombopag.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two medicines to help raise platelet counts in people with persistent or chronic immune thrombocytopenia (ITP) whose platelets are still low after standard treatments. The goal is to see if this combination works better and is safe.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
This study compares two treatments for people with ITP (low platelets) whose condition didn't improve after steroids. One group gets only eltrombopag (a platelet booster pill) and the other gets eltrombopag plus ripertamab (an experimental antibody). The goal is to see if the combination works better at raising platelet levels.
Hear when a new Thrombocytopenia Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.